Panakeia
Entrepreneur First '19London, GB · Founded 2019 · 27 employees on LinkedIn · 3 known investors
Find your way into Panakeia
385 people in our graph share verified history with the Panakeia team — schools, employers, funds. One of them is your warm intro.
Panakeia develops software for biomarker profiling aimed at making precision diagnostics faster and instrument-free, to inform cancer diagnosis, treatment, and drug development. Its solutions target clinicians and researchers working in precision medicine and oncology.
Also known as Panakeia Technologies
Founders & leadership
Panakeia was founded in 2019 by Pahini Pandya, Pandu Raharja, Pandu Raharja-Liu, and Pahini P..
Investors · 3
Company profile
researched Aug 2026Panakeia develops an artificial-intelligence platform that produces molecular and biomarker profiling results directly from routine H&E-stained tissue images, positioning it as an alternative to running multiple physical laboratory assays over days or weeks. The company states that its analysis returns results in minutes and at lower cost than conventional methods, and that it serves both clinical diagnostics and drug development use cases [0][1][2].
The offering is split into two lines. Clinical products cover biomarker profiling across cancer types and other disease areas; the named portfolio item is PANProfiler Breast (ER, PR, HER2), a breast cancer diagnostic that reports tissue ER, PR and HER2 status from H&E slides and integrates with existing digital pathology workflows. The research and drug development line gives pharmaceutical and academic customers access to the same end-to-end, explainable AI histopathology platform for translational medicine, clinical research and companion diagnostics, including signature discovery, biomarker analytical and clinical validation, and patient selection for trials. Customers can add other stains or omics data, and Panakeia offers accompanying expertise in AI, data science, pathology, translational medicine and software-as-a-medical-device regulation, plus access to its clinical partner network [2][4].
The team combines machine learning staff (machine learning lead, engineers and scientists), engineering and software roles, FRCPath-qualified pathologists, and a quality/regulatory lead, under co-founder and CEO Pahini Pandya. The board is chaired by Richard Foster and includes Julia Hawkins (LocalGlobe) and Chris Wheatcroft (Ascension), with Hussein Kanji (Hoxton Ventures) as observer [3]."]
Founding story
According to the company, Panakeia originated from a patient-centred motivation: co-founder and CEO Pahini Pandya observed first-hand the anxiety experienced by patients and families awaiting a cancer diagnosis, and sought to apply roughly a decade of work in cancer research to shortening that wait. She co-founded the company through Entrepreneur First with the stated aim of making precision medicine accessible internationally [3].
Business model
Panakeia sells AI-based biomarker profiling in two channels: regulated clinical diagnostic products supplied to hospitals and laboratories, and a customizable platform plus associated expert services licensed to research and drug development organisations for translational medicine, clinical research and companion diagnostic programmes [0][2].
The sources describe product and platform offerings to hospitals/labs and to research and pharmaceutical customers, but do not disclose pricing, contract structures or revenue figures [0][2].
Traction
Publicly cited traction consists of a UKCA/CE-marked IVD product (PANProfiler Breast), a clinical validation publication on rapid AI molecular profiling for colorectal cancer announced in January, metabolic and pathway activation data in cancers presented at AACR 2026, and named institutional partners and supporters including Cancer Research UK, PathLAKE, King's College London, University College London, University of Leeds and several UK innovation programmes [0][1][2][3].
Latest developments
The company's news feed lists three recent items: a publication of clinical validation showing AI-delivered rapid molecular profiling for colorectal cancer (29 January), an announcement of upcoming scientific and business conference participation (16 April), and the presentation of metabolic and pathway activation data in cancers at AACR 2026 (21 April) [0][1].
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Panakeia positions its image-based profiling as faster and cheaper than existing laboratory-based molecular testing, with its breast product available as an IVD medical device in Great Britain (UKCA) and the EU (CE) but not in the United States. The sources do not provide market share, revenue or competitive benchmarking data [2].
Stated differentiators are extraction of molecular and biomarker information from routine H&E slides alone rather than additional physical tests, minute-scale turnaround, an explainable and diagnostic-grade end-to-end platform, in-house regulatory expertise in software as a medical device, and integration with existing digital pathology workflows [0][2][4].
Technology
The core technology is an end-to-end deep learning platform that infers molecular biomarker status and novel signatures from H&E-stained histopathology specimens, avoiding separate physical assays. The company emphasises diagnostic-grade development under a quality system for medical devices, explainability of model outputs for clinicians and patients, a patent-pending approach aimed at reducing risk, rapid iteration from early development to validation in as little as a few weeks, and the ability to incorporate additional stains or omics data [2][4].
Go-to-market
Direct engagement with hospitals and laboratories for clinical products (with documentation requests and contact routes for medical devices) and partnership-based platform deals with research and drug development organisations; the company also uses scientific and business conference presentations and peer-reviewed publications to reach customers [0][2].
Hospitals, diagnostic laboratories and clinicians requiring biomarker status for patient management; and research organisations and drug developers running translational medicine, clinical research, biomarker validation and companion diagnostic programmes [0][2].
Geography
Regulatory availability of the PANProfiler Breast device is stated for Great Britain (UKCA) and the EU (CE), and it is described as not yet available in the United States. Listed partners and supporters are predominantly UK institutions, including Cancer Research UK, King's College London, University College London, University of Leeds, PathLAKE, Innovate UK, Tech Nation and Digital Catapult [2][3].
History
Panakeia was co-founded via the Entrepreneur First programme by CEO Pahini Pandya, and has since built an interdisciplinary team of clinicians, scientists and engineers, assembled a board including investor representatives from LocalGlobe, Ascension and Hoxton Ventures, obtained UKCA and CE marking for its breast biomarker device, and published clinical validation work [0][2][3].
Risks & controversies
The sources note that PANProfiler Breast is not yet available in the United States, indicating dependence on further regulatory clearance for that market. No controversies are reported in the material reviewed [2].
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Founder mafia
3 people who came through Panakeia went on to found or lead other companies.
Timeline · 4
launches, deals, and filingsPanakeia announced the presentation of metabolic and pathway activation data in cancers at the AACR 2026 conference.
Company news item stating Panakeia will attend and present at upcoming scientific and business conferences.
Panakeia published clinical validation results indicating its AI can deliver rapid molecular profiling for colorectal cancer.
PANProfiler Breast (ER, PR, HER2), which reports tissue ER, PR and HER2 status from H&E slides, is available as an IVD medical device in Great Britain under UKCA and in the EU under CE marking; it is not yet available in the United States.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 8
primary sources listed
- Panakeiapanakeia.ai · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Panakeia do?
- UK company building AI that reads multi-omics and biomarker profiles directly from routine H&E-stained tissue images.
- Who founded Panakeia?
- Panakeia was founded by Pahini Pandya, Pandu Raharja, Pandu Raharja-Liu, Pahini P. in 2019.
- Who are Panakeia's investors?
- Panakeia's investors include Duke Capital Partners, Entrepreneur First, Hoxton Ventures.
- Where is Panakeia headquartered?
- Panakeia is headquartered in London, GB.